Key facts
- It has raised $58.7M; the latest was Early Stage VC ($28.9M) in Mar 2026.
- Notable investors include 5Y Capital, Tailong VC, Guangdong Yuecai Venture Capital, Zhongshan Finance Investment, Fuho Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Leman Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Leman Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Leman Biotech
Developer of novel tumor immunotherapy drugs intended to serve the biotechnology industry. The company focuses on new tumor immunotherapy drugs based on immunometabolic reprogramming & artificial intelligence (AI), and production of biological macromolecular drugs and new immune cell drugs, thereby enabling users to improve immune cell function and enhance therapeutic responsiveness in applications.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2021
- Website
- lemanbio.com/
- Ownership
- Privately Held (backing)
Leman Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Leman Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Leman Biotech in its N-PORT filings yet. We sweep new filings monthly.